Identification of hit compounds with anti-schistosomal activity on in vitro generated juvenile worms in cell-free medium.

ABSTRACT:

Background

Anthelminthic treatment options against schistosomiasis are limited. The current treatment relies almost exclusively on a single drug, praziquantel (PZQ). As a consequence, the development of resistance to PZQ and limited activity of PZQ against earlier development stages are respectively a risk and a limitation to achieving the goals of the new WHO roadmap towards elimination. For the discovery of new chemical starting points, the in vitro drug screening on Schistosoma mansoni (S. mansoni) against newly transformed schistosomula (NTS) is still the most predominant approach. The use of only NTS in the initial screening limits sensitivity to potential new compounds which are predominantly active in later developmental stages. Using our recently described highly standardiz

SUBMITTER: Vejzagic N 

PROVIDER: S-EPMC8191877 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature